ROSETTA GENOMICS (ROSG)

REHOVOT, Israel and JERSEY CITY, New Jersey, October 27
/PRNewswire-FirstCall/ -- Rosetta Genomics Ltd (Nasdaq:ROSG), a leading
developer of microRNA-based diagnostics and therapeutics, announced today it
has launched Rosetta Green, a microRNA-based plant biotechnology project.
Rosetta Green will leverage the extensive knowledge gained at Rosetta
Genomics in microRNAs, as well as its proprietary technologies and strong IP
position, to develop a wide range of plant-based applications. The company
has recently completed a financing round from private investors exclusively
for this project.

"Since our founding in 2000, we have maintained that small non-protein
coding RNA - what we now know are microRNAs - play a critical role in many
cellular processes," said Amir Avniel, CEO of Rosetta Genomics. "There is a
large and growing body of evidence, including research we have been
conducting in-house, pointing to the importance of microRNAs in plants and
algal development, which may have potential applications in a wide range of
plant-based biotech products. We feel it is critical at this point in time to
explore this important field to ensure Rosetta Genomics remains at the
forefront of research, development and commercialization of microRNA-based
products."

MicroRNAs have been established as key regulators of protein expression
and their aberrant regulation in humans is associated with many serious
diseases. However, microRNAs' vast potential is not limited to humans.

Research conducted at Rosetta Green has shown a promising correlation
between the expression of microRNAs and algal oil content. In addition,
correlation has been found between microRNAs and starch & oil content in corn.

"MicroRNAs hold significant potential for the plant biotechnology
industry," noted Dr. Rudy Maor, Head of Research and Development at Rosetta
Green. "Stemming from their role as master regulators of gene expression,
microRNAs are believed to play a critical role in each major step in plant
and algal development and may therefore affect biotech-related traits such as
oil and starch content, stress-tolerance, growth rate, yield, and more."

"Using Rosetta Genomics' unique microRNA technologies and strong IP, our
goal is to develop a wide range of solutions that will assist companies in
addressing critical unmet needs, " said Dr. Dalia Cohen, Chief Scientific
Officer at Rosetta Genomics. "Through collaborations with strategic partners
in the plant biotech industry, we intend to develop novel solutions using the
unique potential microRNAs hold."

About microRNAs

MicroRNAs (miRNAs) are naturally occurring, short non-coding RNAs that
regulate gene expression in plants, humans, and have been recently discovered
in algae. The ability to selectively regulate gene expression through
microRNAs could provide the means to enhance a wide range of plant and algal
characteristics which are of high value to the plant biotech industry.

About Rosetta Genomics

Rosetta Genomics (Nasdaq: ROSG) is a leader in the field of microRNAs.
Founded in 2000, the company's integrative research platform combining
bioinformatics and state-of-the-art laboratory processes has led to the
discovery of hundreds of biologically validated novel human microRNAs.
Building on its strong IP position and proprietary platform technologies,
Rosetta Genomics is working on the application of these technologies in the
development of a full range of microRNA-based diagnostic and therapeutic
tools, focusing primarily on cancer and various women's health indications.
The first microRNA diagnostic test applying Rosetta Genomics' technology has
been approved for clinical use by the State of New York, and the company
expects it will be launched by licensed clinical laboratories in the United
States in 2008. For more information, please visit
http://www.rosettagenomics.com

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's future
expectations, plans and prospects, including without limitation, statements
relating to: the potential to use microRNA-based molecular breeding to
develop algal strains and non-food crops for improved biofuel production; the
receipt of additional financing when certain milestones have been met and the
role of microRNAs in plant and algal physiology and development constitute
forward-looking statements for the purposes of the safe harbor provisions
under The Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by these forward-looking
statements as a result of various important factors, including the risks more
fully discussed in the "Risk Factors" section of Rosetta's Annual Report on
Form 20-F for the year ended December 31, 2007 as filed with the Securities
and Exchange Commission. In addition, any forward-looking statements
represent Rosetta's views only as of the date of this release and should not
be relied upon as representing its views as of any subsequent date. Rosetta
does not assume any obligation to update any forward-looking statements
unless required by law.

SOURCE Rosetta Genomics Ltd